Legislative Progress for Therapeutic Psilocybin in Minnesota
Minnesota House lawmakers have approved legislation to allow for the regulated use of therapeutic psilocybin for adults aged 21 and older. The reform was integrated into a broader health policy bill through an amendment, which passed the House of Representatives with a 114-15 vote. This amended legislation now proceeds to the Senate for further consideration, as reported by Marijuana Moment.
Rep. Andy Smith (DFL), who sponsored the amendment, stated that psilocybin has shown potential in supporting individuals with various mental health conditions, including depression, addiction recovery, and post-traumatic stress disorder (PTSD), particularly among veterans and public safety officers. The proposed program would allow qualified patients to receive psilocybin-assisted therapy in approved private residences or licensed treatment facilities, administered by a registered facilitator.
Program Structure and Oversight
- Facilitator Licensing: The program would initially license 20 to 50 facilitators.
- Testing Facilities: At least three approved testing facilities for psilocybin would be required.
- Patient Cap: A limit of 1,000 patients would be set for the first three years of the law’s implementation.
- Oversight: The Office of Cannabis Management (OCM) would oversee the program and establish rules, supported by a new Psychedelic Medicine Advisory Committee.
- Therapy Sessions: Sessions would involve three phases: a preparation consultation, the administration of the psychedelic, and an integration phase for processing the therapeutic experience.
Reps. Max Rymer (R) and Nolan West (R) highlighted the potential for Minnesota to access federal funds for psychedelic research, citing a recent executive order signed by President Donald Trump. They emphasized that early state action could position Minnesota to benefit from these resources, which are intended to support research into alternative approaches for severe conditions. The Senate Finance Committee also adopted an amendment directing the OCM to analyze federal programs for funding a state psilocybin therapeutic use program.
Louisiana Establishes Psychedelic-Assisted Therapy Pilot Program
In a parallel development, Louisiana lawmakers have passed a bill to create a psychedelic-assisted therapy pilot program. This initiative, sponsored by Sen. Patrick McMath (R), will utilize opioid settlement dollars to fund clinical trials for alternative approaches such as psilocybin, ibogaine, and MDMA. The House of Representatives approved the amended proposal with a 97-0 vote, following unanimous passage in the Senate. Due to a House amendment adding MDMA, the bill will return to the Senate for a final vote before potentially reaching Governor Jeff Landry (R)’s desk, as reported by Marijuana Moment.
Rep. Neil Riser (R) presented the legislation to the House, underscoring the critical need for alternative approaches for military veterans and first responders experiencing PTSD. He also referenced President Trump’s executive order, noting that the inclusion of MDMA aligns Louisiana with federal research priorities. As previously reported by Hemp Gazette, other states like Maryland have also extended task forces to develop therapeutic access frameworks for psychedelics, and federal efforts are underway to advance veterans’ psychedelic therapy research.
Program Requirements and Research Focus
- Oversight: The Louisiana Department of Health (LDH) would oversee the program, facilitating clinical trials.
- Eligible Participants: Individuals with opioid use disorders, co-occurring substance use disorders, and conditions that have not responded to other neurological or mental health interventions.
- Regulatory Compliance: All studies must undergo the federal Food and Drug Administration (FDA) investigational drug approval process, and researchers must obtain permits from the Drug Enforcement Administration (DEA) for Schedule I controlled substances.
- Safety Protocols: The program mandates mental and physical health screening for patients, robust safety and compliance processes, adverse event reporting, and training and licensing for therapists.
- Collaboration and Revenue: Academic institutions are encouraged to collaborate in clinical trials to enhance FDA approval prospects. The bill includes a revenue-sharing requirement, directing at least 2.5 percent of net sales from any approved drug to the state, with additional provisions for a national research consortium.
Expanding Access to Therapeutic Psychedelics
These legislative actions in Minnesota and Louisiana reflect a growing trend among U.S. states to explore regulated pathways for therapeutic psilocybin and other psychedelics. The focus remains on structured, medically supervised programs aimed at addressing specific health conditions, particularly mental health disorders and addiction. The emphasis on federal funding and collaboration with federal agencies like the FDA and DEA indicates a strategic approach to integrate these therapies within established medical and regulatory frameworks.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
